Results 61 to 70 of about 12,025 (204)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

International Journal of COPD, 2016
Maria Gabriella Matera,1 Alessandro Sanduzzi,2 Mario Cazzola3 1Department of Experimental Medicine, Second University of Naples, 2Department of Respiratory Diseases, Monaldi Hospital, University Federico II, Naples, 3Department of Systems Medicine ...
Matera MG, Sanduzzi A, Cazzola M
doaj  

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Медицинский совет, 2018
The paper is devoted to the problem of clinical efficacy and pharmacoeconomic evaluation of Spiolto Respimat. The results of clinical trials prove that Spiolto Respimat in patients with COPD improves spirometric values, symptoms of dyspnea and health ...
S. K. Zyryanov, Y. A. Galatonova
doaj   +1 more source

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

Allergy, EarlyView.
This study distinguishes severe asthma–related airway transcriptomic changes from the effects of high‐dose ICS. Most dysregulated genes in severe asthma show concordance with corticosteroid responses. Corticosteroid‐resistant T2‐high asthma featured T2‐high and epithelial barrier gene upregulation, while T2‐low asthma featured Th1/IL‐17 signatures. ASM,
Jiashu Shen, Rekha Chaudhuri, Stephen Bicknell, Adel H. Mansur, Rahul Shrimanker, Ian D. Pavord, Stephen J. Fowler, Vanessa Brown, Lorcan P. McGarvey, Peter H. Howarth, Sven‐Erik Dahlén, Ian M. Adcock, Nazanin Zounemat‐Kermani, Joseph R. Arron, Liam G. Heaney, David F. Choy, Timothy S. C. Hinks, Emanuele Marchi, Peter Bradding, on behalf of the UK Medical Research Council Refractory Asthma Stratification programme (RASP‐UK)   +19 more
wiley   +1 more source

Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation

Therapeutics and Clinical Risk Management, 2019
 Ho Cheol Kim,1,* Tae Hoon Kim,2,* Chin Kook Rhee,3 Minkyu Han,4 Yeon-Mok Oh1 1Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2Department of Internal Medicine, CHA ...
Kim HC, Kim TH, Rhee CK, Han M, Oh YM
doaj  

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid

International Journal of COPD, 2022
Marc Miravitlles,1 Katia Verhamme,2 Peter MA Calverley,3 Michael Dreher,4 Valentina Bayer,5 Asparuh Gardev,6 Alberto de la Hoz,6 Jadwiga Wedzicha,7 David Price8,9 1Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research ...
Miravitlles M, Verhamme K, Calverley PMA, Dreher M, Bayer V, Gardev A, de la Hoz A, Wedzicha J, Price D   +8 more
doaj  

Phase coupling between eye and brain pulsations is bidirectional and modulated by the parasympathetic system – An fMREye study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Physiological pulsations driven by cardiac, respiratory, and vasomotor activity are essential for solute transport within perivascular and perineural cerebrospinal fluid (CSF) pathways that support brain and eye clearance systems. Previous studies have shown that parasympathetic blockade significantly reduces ocular pulsation power and
Ebrahimi Seyed‐Mohsen, Väyrynen Tommi, Huotari Niko, Saarela Ville, Honkamo Marja, Helakari Heta, Järvelä Matti, Korhonen Vesa, Raitamaa Lauri, Kiviniemi Vesa   +9 more
wiley   +1 more source

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan

International Journal of COPD, 2018
Hideyasu Yamada,1,2 Norihito Hida,2 Nobuyuki Hizawa1 1Department of Pulmonology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan; 2Department of Respiratory Medicine, Hitachinaka General Hospital, Hitachi ...
Yamada H, Hida N, Hizawa N
doaj  

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments

International Journal of COPD, 2015
Frank Trudo,1 David M Kern,2 Jill R Davis,1 Ozgur Tunceli,2 Siting Zhou,2 Emma L Graham,3 Charlie Strange,4 Setareh A Williams1 1AstraZeneca Pharmaceuticals LP, 2HealthCore, Inc., Wilmington, DE, USA; 3AstraZeneca Pharmaceuticals LP, Alderley Park ...
Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA   +7 more
doaj  

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source